Stereotaxis, Inc. (STXS)

NYSEAMERICAN: STXS · Real-Time Price · USD
1.920
+0.040 (2.13%)
At close: May 12, 2026, 4:00 PM EDT
1.820
-0.100 (-5.21%)
After-hours: May 12, 2026, 5:42 PM EDT
Market Cap187.16M +10.5%
Revenue (ttm)32.38M +20.3%
Net Income-22.91M
EPS-0.25
Shares Out 97.48M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume388,560
Open1.880
Previous Close1.880
Day's Range1.850 - 1.950
52-Week Range1.740 - 3.590
Beta1.33
AnalystsStrong Buy
Price Target4.00 (+108.33%)
Earnings DateMay 12, 2026

About STXS

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Na... [Read more]

Sector Healthcare
IPO Date Aug 12, 2004
Employees 131
Stock Exchange NYSEAMERICAN
Ticker Symbol STXS
Full Company Profile

Financial Performance

In 2025, Stereotaxis's revenue was $32.38 million, an increase of 20.28% compared to the previous year's $26.92 million. Losses were -$22.91 million, -9.62% less than in 2024.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for STXS stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 108.33% from the latest price.

Price Target
$4.0
(108.33% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Stereotaxis Earnings Call Transcript: Q1 2026

Q1 2026 revenue declined year-over-year amid a transition from legacy products, but new robotic systems and catheters are gaining regulatory approvals and early commercial traction. Guidance for double-digit revenue growth and over $40 million in annual revenue is reiterated, with recurring revenue expected to drive profitability.

1 hour ago - Transcripts

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

ST. LOUIS, May 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates...

2 hours ago - GlobeNewsWire

Stereotaxis Announces First MAGiC Procedures in the United States

ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first pat...

20 days ago - GlobeNewsWire

Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026

ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will ...

21 days ago - GlobeNewsWire

Stereotaxis Transcript: M&A announcement

The acquisition of Robocath brings complementary robotic technology, accelerating the strategy to lead in endovascular procedures. The deal includes up to $45 million in payments, targets a $20–30 billion market, and expects break-even by year three post-close.

27 days ago - Transcripts

Stereotaxis to acquire Robocath, terms undisclosed

Stereotaxis (STXS) announced that it has entered into a definitive agreement to acquire Robocath. Stereotaxis estimates that Robocath will contribute approximately $2M in annual revenue during the fir...

27 days ago - TheFly

Stereotaxis Announces Definitive Agreement to Acquire Robocath

ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today annou...

27 days ago - GlobeNewsWire

Stereotaxis receives FDA clearance for Synchrony system

Stereotaxis (STXS) announced that it has received FDA 510(k) clearance for the Synchrony system. “Synchrony and SynX are central to our digital surgery efforts to modernize the interventional lab with...

5 weeks ago - TheFly

Stereotaxis Announces FDA Clearance and Launch of Synchrony System

ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has r...

5 weeks ago - GlobeNewsWire

Stereotaxis files $100M mixed securities shelf

16:26 EDT Stereotaxis (STXS) files $100M mixed securities shelf

2 months ago - TheFly

Stereotaxis management to meet virtually with BTIG

Virtual Meeting to be held on March 24 hosted by BTIG.

2 months ago - TheFly

Stereotaxis Earnings Call Transcript: Q4 2025

Delivered 36% Q4 revenue growth and launched new robotic and catheter products after key regulatory approvals. Manufacturing ramp and transition to proprietary catheters are underway, with double-digit revenue growth and margin expansion expected in 2026.

2 months ago - Transcripts

Stereotaxis reports Q4 EPS (6c), consensus (6c)

Reports Q4 revenue $8.64M, consensus $9.24M. System backlog at the start of 2026 is $9.1M. “The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad...

2 months ago - TheFly

Stereotaxis sees FY26 revenue up double digits

The company said, “Stereotaxis (STXS) anticipates double digit revenue growth for the full year 2026. Both system and recurring revenue are expected to increase over the course of the year…

2 months ago - TheFly

Stereotaxis Reports 2025 Full Year Financial Results

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu...

2 months ago - GlobeNewsWire

Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026

ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

3 months ago - GlobeNewsWire

Stereotaxis announces launch of electrophysiology program at Klinikum Furth

Stereotaxis (STXS) announced the launch of a new robotic electrophysiology program at Klinikum Furth in Furth, Germany. Klinikum Furth is the first hospital in Germany to establish a leading heart…

3 months ago - TheFly

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of ...

3 months ago - GlobeNewsWire

Stereotaxis reports FDA approval for MAGiC Ablation Catheter

Stereotaxis (STXS) announced it obtained U.S. Food and Drug Administration approval for the MAGiC Magnetic Interventional Ablation Catheter. “FDA approval of MAGiC is a significant milestone for Stere...

4 months ago - TheFly

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U....

4 months ago - GlobeNewsWire

Stereotaxis initiated with an Outperform at Citizens

Citizens initiated coverage of Stereotaxis (STXS) with an Outperform rating and $4 price target Stereotaxis develops robotic platforms for use in endovascular surgeries, the analyst tells investors in...

5 months ago - TheFly

Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference

ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the compa...

6 months ago - GlobeNewsWire

Stereotaxis reports Q3 EPS (7c), consensus (6c)

Reports Q3 revenue $7.46M, consensus $8.38M. “We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory and development milestones,” sai...

6 months ago - TheFly

Stereotaxis Reports 2025 Third Quarter Financial Results

ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...

6 months ago - GlobeNewsWire